Improvement of in Vivo Expression of Genes Delivered by Self-Amplifying RNA Using Vaccinia Virus Immune Evasion Proteins

Human Gene Therapy

Volumn 28, Issue 12, 2017, Pages 1138-1146

  Beissert, Tim ^a   Koste, Lars ^b   Perkovic, Mario ^a   Walzer, Kerstin C ^c   Erbar, Stephanie ^c   Selmi, Abderraouf ^a   Diken, Mustafa ^a   Kreiter, Sebastian ^a   Türeci, Özlem ^d   Sahin, Ugur ^a,b,c  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c BIONTECH AG   (Germany)

^d Cluster for Individualized Immune Intervention   (Germany)

Author keywords

alphavirus; replicon; self amplifying RNA; vaccinia virus B18; vaccinia virus E3; vaccinia virus K3

Indexed keywords

BETA INTERFERON; INTERFERON; MESSENGER RNA; PATTERN RECOGNITION RECEPTOR; SELF AMPLIFYING RNA; UNCLASSIFIED DRUG; VACCINIA VIRUS IMMUNE EVASION PROTEIN; VACCINIA VIRUS IMMUNE EVASION PROTEIN B18; VACCINIA VIRUS IMMUNE EVASION PROTEIN E3; VACCINIA VIRUS IMMUNE EVASION PROTEIN K3; VIRAL PROTEIN; VIRUS RNA; PROTEIN KINASE R; PROTEIN KINASE R, MOUSE; RNA;

ANIMAL EXPERIMENT; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE RESPONSE; HOST RESISTANCE; HUMAN; HUMAN CELL; IMMUNE EVASION; IN VITRO GENE TRANSFER; IN VIVO GENE TRANSFER; INNATE IMMUNITY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PROTEIN INDUCTION; RNA DEGRADATION; RNA REPLICATION; RNA TRANSLATION; RNA VECTOR; UPREGULATION; VACCINIA VIRUS; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL LINE; FEMALE; GENE EXPRESSION; GENE TRANSFER; GENE VECTOR; GENETICS; METABOLISM;

ANIMALS; CELL LINE; EIF-2 KINASE; FEMALE; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; IMMUNE EVASION; MICE; MICE, INBRED BALB C; RNA; VACCINIA VIRUS; VIRAL PROTEINS;

EID: 85039792639     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2017.121     Document Type: Conference Paper

References (25)

1. Lundstrom K. Biology and application of alphaviruses in gene therapy. Gene Ther 2005;12:S92-S97.
2. Geall AJ, Verma A, Otten GR, et al. Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A 2012;109:14604-14609.
3. McNab F, Mayer-Barber K, Sher A, et al. Type I interferons in infectious disease. Nat Rev Immunol 2015;15:87-103.
4. Leitner WW, Hwang LN, deVeer MJ, et al. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med 2003;9:33-39.
5. Brito LA, Chan M, Shaw CA, et al. A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol Ther 2014;22:2118-2129.
6. Pindel A, Sadler A. The role of protein kinase R in the interferon response. J Interferon Cytokine Res 2011;31:59-70.
7. Ventoso I, Sanz MA, Molina S, et al. Translational resistance of late alphavirus mRNA to eIF2alpha phosphorylation: a strategy to overcome the antiviral effect of protein kinase PKR. Genes Dev 2006;20:87-100.
8. Ventoso I. Adaptive changes in alphavirus mRNA translation allowed colonization of vertebrate hosts. J Virol 2012;86:9484-9494.
9. Gorchakov R, Frolova E, Williams BR, et al. PKRdependent and-independent mechanisms are involved in translational shutoff during Sindbis virus infection. J Virol 2004;78:8455-8467.
10. Perdiguero B, Esteban M. The interferon system and vaccinia virus evasion mechanisms. J Interferon Cytokine Res 2009;29:581-598.
11. Poleganov MA, Eminli S, Beissert T, et al. Efficient reprogramming of human fibroblasts and bloodderived endothelial progenitor cells using nonmodified RNA for reprogramming and immune evasion. Hum Gene Ther 2015;26:751-766.
12. Phua KKL, Liu Y, Sim SH. Non-linear enhancement of mRNA delivery efficiencies by influenza A derived NS1 protein engendering host gene inhibition property. Biomaterials 2017;133:29-36.
13. Kuhn AN, Diken M, Kreiter S, et al. Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo. Gene Ther 2010;17:961-971.
14. Holtkamp S, Kreiter S, Selmi A, et al. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 2006;108:4009-4017.
15. Domingo-Gil E, Toribio R, Najera JL, et al. Diversity in viral anti-PKR mechanisms: a remarkable case of evolutionary convergence. PLoS One 2011;6:e16711.
16. Ehrengruber MU, Lundstrom K. Semliki Forest virus and Sindbis virus vectors. Curr Protoc Hum Genet 2002;Chapter 12, Unit 12. 2.
17. Kreiter S, Konrad T, SesterM, et al. Simultaneous ex vivo quantification of antigen-specific CD4+ and CD8+ T cell responses using in vitro transcribed RNA. Cancer Immunol Immunother 2007;56:1577-1587.
18. Karlsson JO, Ostwald K, Kabjorn C, et al. A method for protein assay in Laemmli buffer. Anal Biochem 1994;219:144-146.
19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T) Method. Methods 2001;25:402-408.
20. Chinsangaram J, Piccone ME, Grubman MJ. Ability of foot-and-mouth disease virus to form plaques in cell culture is associated with suppression of alpha/ beta interferon. J Virol 1999;73:9891-9898.
21. Warren L, Manos PD, Ahfeldt T, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010;7:618-630.
22. Hall MP, Unch J, Binkowski BF, et al. Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate. ACS Chem Biol 2012;7:1848-1857.
23. Davies MV, Chang HW, Jacobs BL, et al. The E3L and K3L vaccinia virus gene products stimulate translation through inhibition of the doublestranded RNA-dependent protein kinase by different mechanisms. J Virol 1993;67:1688-1692.
24. Romano PR, Zhang F, Tan SL, et al. Inhibition of double-stranded RNA-dependent protein kinase PKR by vaccinia virus E3: role of complex formation and the E3 N-terminal domain. Mol Cell Biol 1998;18:7304-7316.
25. Rivas C, Gil J, Mebrevelková Z, et al. Vaccinia virus E3L protein is an inhibitor of the interferon (i. f. n.)-induced 2-5A synthetase enzyme. Virology 1998;243:406-414.